Tag: SUNRISE-FA

LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy

LX2006 is the first investigational gene therapy for the treatment of Friedreich’s ataxia cardiomyopathy Initial data from the first two cohorts, including myocardial protein expression and biomarkers measuring serum and cardiac structure and function, expected in the first half of […]